Should I buy or sell Exact Sciences stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks .

What is Exact Sciences' stock price target for 2024?

18 brokers have issued 1 year price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they anticipate the company's share price to reach $96.11 in the next year. This suggests a possible upside of 29.9% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts .

How have EXAS shares performed in 2023?

Exact Sciences' stock was trading at $49.51 at the beginning of the year. Since then, EXAS shares have increased by 49.4% and is now trading at $73.98. View the best growth stocks for 2023 here .

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our EXAS earnings forecast .

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.05. The medical research company had revenue of $622.10 million for the quarter, compared to analyst estimates of $601.14 million. Exact Sciences had a negative trailing twelve-month return on equity of 9.19% and a negative net margin of 11.73%. Exact Sciences's revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.94) earnings per share.

What ETFs hold Exact Sciences' stock?

ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , ARK Innovation ETF (ARKK) , Principal Healthcare Innovators ETF (BTEC) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Simplify Health Care ETF (PINK) , First Trust NYSE Arca Biotechnology Index Fund (FBT) and VanEck Biotech ETF (BBH) .

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com . Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX) , NVIDIA (NVDA) , Alibaba Group (BABA) , Micron Technology (MU) , Salesforce (CRM) , PayPal (PYPL) , Block (SQ) , Advanced Micro Devices (AMD) , Walt Disney (DIS) and AbbVie (ABBV) .

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc.. Read More

NASDAQ:EXAS

Exact Sciences (EXAS) Stock Price, News & Analysis

$73.98

-1.74 (-2.30%)

(As of 12/29/2023 ET)

Compare

Today's Range: $73.20
▼
$76.18
50-Day Range: $59.06
▼
$75.72
52-Week Range: $45.88
▼
$100.77

Volume: 987,339 shs
Average Volume: 1.76 million shs
Market Capitalization: $13.38 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $96.11

Exact Sciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 29.9% Upside
$96.11 Price Target
Short Interest: Healthy
3.92% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: 1.32
Based on 6 Articles This Week
Insider Trading: Selling Shares
$1 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.48) to ($1.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

41st out of 950 stocks

Medical Laboratories Industry

3rd out of 20 stocks

4.4

Analyst's Opinion

Consensus Rating
Exact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $96.11, Exact Sciences has a forecasted upside of 29.9% from its current price of $73.98.
Amount of Analyst Coverage
Exact Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
3.92% of the outstanding shares of Exact Sciences have been sold short.
Short Interest Ratio / Days to Cover
Exact Sciences has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Exact Sciences has recently decreased by 3.54%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Exact Sciences does not currently pay a dividend.
Dividend Growth
Exact Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.
Environmental Sustainability
The Environmental Impact score for Exact Sciences is -0.83.

3.0

News and Social Media Coverage

News Sentiment
Exact Sciences has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Exact Sciences this week, compared to 8 articles on an average week.
Search Interest
Only 17 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.
MarketBeat Follows
7 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,004,835.00 in company stock.
Percentage Held by Insiders
Only 1.30% of the stock of Exact Sciences is held by insiders.
Percentage Held by Institutions
89.13% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Exact Sciences are expected to grow in the coming year, from ($1.48) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exact Sciences is -46.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exact Sciences is -46.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exact Sciences has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Exact Sciences Stock (NASDAQ:EXAS)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EXAS Stock News Headlines

December 30, 2023 | americanbankingnews.com

Exact Sciences Co. (NASDAQ:EXAS) Given Average Recommendation of "Moderate Buy" by Brokerages

December 25, 2023 | finance.yahoo.com

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 31% Below Their Intrinsic Value Estimate

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 20, 2023 | msn.com

Guardant Health stock slides, Exact Sciences gains amid FDA update

December 17, 2023 | fool.com

1 Supercharged Growth Stock to Buy Before It Soars as Much as 222%, According to Cathie Wood's Ark Invest

December 15, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Exact Sciences Amid Long-Term Growth Potential and Expanded Market Reach

December 15, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Exact Sciences

December 15, 2023 | msn.com

Guggenheim Initiates Coverage of Exact Sciences (EXAS) with Buy Recommendation

December 31, 2023 | Behind the Markets (Ad)

New Year's Sale: Get 12 Months of Stock Picks for $9.00

Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.

December 14, 2023 | msn.com

Wolfe Research Initiates Coverage of Exact Sciences (EXAS) with Outperform Recommendation

December 13, 2023 | finance.yahoo.com

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?

December 7, 2023 | finance.yahoo.com

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

December 4, 2023 | finance.yahoo.com

Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?

December 1, 2023 | markets.businessinsider.com

Strong IP Portfolio and Market Position Justify Buy Rating for Exact Sciences

December 1, 2023 | msn.com

Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?

December 1, 2023 | insidermonkey.com

Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3

November 30, 2023 | finance.yahoo.com

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

November 28, 2023 | finance.yahoo.com

Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain

November 20, 2023 | finance.yahoo.com

Wall Street Analysts See a 51.73% Upside in Exact Sciences (EXAS): Can the Stock Really Move This High?

November 17, 2023 | msn.com

Exact Sciences sues Geneoscopy for alleged patent infringement

November 17, 2023 | msn.com

Exact Sciences Sues Rival Geneoscopy Related To Colon Cancer Test Cologuard Patent

November 17, 2023 | markets.businessinsider.com

Exact Sciences Files Lawsuit Against Geneoscopy For Infringing Patented Technology

November 17, 2023 | finance.yahoo.com

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

November 14, 2023 | bizjournals.com

One Wisconsin firm makes Deloitte Technology Fast 500 list. It's not Exact Sciences.

November 6, 2023 | finance.yahoo.com

Exact Sciences (EXAS) Just Overtook the 20-Day Moving Average

November 4, 2023 | morningstar.com

Exact Sciences Corp EXAS

November 3, 2023 | nasdaq.com

Exact Sciences Rings the Closing Bell

See More Headlines

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/01/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:EXAS
CUSIP: 30063P10
CIK: 1124140
Web: www.exactsciences.com
Phone: (608) 284-5700
Fax: 608-284-5701
Employees: 6,400
Year Founded: 1995

Price Target and Rating

Average Stock Price Target: $96.11
High Stock Price Target: $130.00
Low Stock Price Target: $73.00
Potential Upside/Downside: +29.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-623,510,000.00
Net Margins: -11.73%
Pretax Margin: -11.69%
Return on Equity: -9.19%
Return on Assets: -4.46%

Debt

Debt-to-Equity Ratio: 0.74
Current Ratio: 2.41
Quick Ratio: 2.13

Sales & Book Value

Annual Sales: $2.08 billion
Price / Sales: 6.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $17.13 per share
Price / Book: 4.32

Miscellaneous

Outstanding Shares: 180,850,000
Free Float: 178,499,000
Market Cap: $13.38 billion
Optionable: Optionable
Beta: 1.42

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Kevin T. Conroy (Age 57)
Chairman of The Board & CEO
Comp: $1.54M
Mr. Jeffrey T. Elliott CFA (Age 45)
Executive VP & CFO
Comp: $518.13k
Ms. Sarah Condella (Age 42)
Executive Vice President of Human Resources
Comp: $742.76k
Mr. Everett V. Cunningham (Age 57)
Chief Commercial Officer
Comp: $1.34M
Dr. Jorge A. Garces Ph.D. (Age 51)
Chief Science Officer
Ms. Megan Jones
Associate Manager of Investor Relations
Mr. Tim Caprez
Chief Compliance Counsel & VP
Mr. James Herriott (Age 43)
Senior VP, General Counsel & Secretary
Mr. Vic Parker
Head of Sales
Ms. Kristen Weiler
Vice President of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EXAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?: 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares.
View EXAS analyst ratings or view top-rated stocks.
What is Exact Sciences' stock price target for 2024?: 18 brokers have issued 1 year price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they anticipate the company's share price to reach $96.11 in the next year. This suggests a possible upside of 29.9% from the stock's current price.
View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts.
How have EXAS shares performed in 2023?: Exact Sciences' stock was trading at $49.51 at the beginning of the year. Since then, EXAS shares have increased by 49.4% and is now trading at $73.98.
View the best growth stocks for 2023 here.
When is Exact Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our EXAS earnings forecast.
How were Exact Sciences' earnings last quarter?: Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.05. The medical research company had revenue of $622.10 million for the quarter, compared to analyst estimates of $601.14 million. Exact Sciences had a negative trailing twelve-month return on equity of 9.19% and a negative net margin of 11.73%. Exact Sciences's revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.94) earnings per share.
What ETFs hold Exact Sciences' stock?: ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Innovation ETF (ARKK), Principal Healthcare Innovators ETF (BTEC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT) and VanEck Biotech ETF (BBH).

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?: 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.
What other stocks do shareholders of Exact Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).
How do I buy shares of Exact Sciences?: Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Exact Sciences have any subsidiaries?: The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More

This page (NASDAQ:EXAS) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial